Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pharmacotherapy

• Publication date

  2015-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/phar.1643PMID 26497482
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune Checkpoint Blockade in Cancer Therapy.

  2015cited by this paper
• Toxicities of Immunotherapy for the Practitioner.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma

  2015cited by this paper
• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Improved overall survival in melanoma with combined dabrafenib and trametinib.

  2015cited by this paper
• First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.

  2015cited by this paper
• Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.

  2015cited by this paper
• Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC).

  2015cited by this paper
• Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Ipilimumab in patients with melanoma and autoimmune disease

  2014cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

  2014cited by this paper
• Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

  2013cited by this paper
• Ipilimumab and its toxicities: a multidisciplinary approach.

  2013cited by this paper
• Endocrine side effects induced by immune checkpoint inhibitors.

  2013cited by this paper
• Bristol-Myers Squibb presenterar resultat från den första fas 1-studien på patienter med avancerat melanom som kombinerar de två immunsignalvägshämmarna nivolumab och Yervoy® (ipilimumab)

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Therapy for metastatic melanoma: the past, present, and future

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.

  2008cited by this paper
• Cancer-related inflammation

  2008cited by this paper
• A history of cancer chemotherapy.

  2008cited by this paper
• Mechanisms of immune evasion by tumors.

  2006cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper
• Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

  2005cited by this paper
• Monoclonal antibodies as therapeutic agents for cancer.

  2004cited by this paper
• Application of IL-2 and other cytokines in renal cancer

  2004cited by this paper
• Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

  2000cited by this paper
• Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

  2000cited by this paper
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper

• Identification of a C2H2 zinc finger-related lncRNA prognostic signature and its association with the immune microenvironment in clear cell renal cell carcinoma

  2025cites this paper
• Integrating artificial intelligence into small molecule development for precision cancer immunomodulation therapy

  2025cites this paper
• Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment

  2025cites this paper
• Development, Validation, and Silent Trial of a Predictive Model for Acute Care Use in Cancer Patients on Immunotherapy

  2025cites this paper
• Advances in STING Pathway Modulation for Cancer and Immunotherapy: A Comprehensive Review of Preclinical and Clinical Studies (2020–2024)

  2025cites this paper
• Application of Gene Therapy to Oral Diseases

  2025cites this paper
• Immune checkpoint inhibitor (ICI) therapy in central nervous system cancers: State-of-the-art and future outlook.

  2025cites this paper
• Hematological ratios, immune-related adverse events and mortality in patients treated with immune checkpoint inhibitors

  2025cites this paper
• A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer

  2024cites this paper
• Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapy

  2024cites this paper
• High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial

  2024cites this paper
• Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies

  2024cites this paper
• Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM

  2024cites this paper
• Emerging druggable targets for immune checkpoint modulation in cancer immunotherapy: the iceberg lies beneath the surface

  2024cites this paper
• Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy

  2024cites this paper
• Integrating immune multi-omics and machine learning to improve prognosis, immune landscape, and sensitivity to first- and second-line treatments for head and neck squamous cell carcinoma

  2024cites this paper
• The ClearPoint Array® frame: an MRI compatible system that supports non-craniotomy, multi-trajectory (NCMT) stereotactic procedures.

  2024cites this paper
• Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors

  2024cites this paper
• Emerging Futuristic Targeted Therapeutics

  2023cites this paper
• PD-L1 expression is linked to tumor-infiltrating T cell exhaustion and adverse pathological behavior in pheochromocytoma/paraganglioma.

  2023cites this paper
• Safety of dendritic cell and cytokine-induced killer (DC-CIK) cell-based immunotherapy in patients with solid tumor: a retrospective study in China.

  2023cites this paper
• Nivolumab Safety in Renal Cell Carcinoma: A Case Report

  2023cites this paper
• Prognostic importance of PD-L1 expression in bladder cancer patients

  2023cites this paper
• Challenges and Strategies for Improving Access to Cancer Drugs in Malaysia: Summary of Opinions Expressed at the 2nd MACR International Scientific Conference 2022

  2023cites this paper
• Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review

  2023cites this paper
• Universal cell donor lines: A review of the current research

  2023cites this paper
• Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies

  2023cites this paper
• Prognostic and immunotherapeutic significance of immunogenic cell death-related genes in colon adenocarcinoma patients

  2023cites this paper
• Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes

  2023cites this paper
• TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer

  2023cites this paper
• [Latest Findings on the Function of Immune Metabolism in Tumor Immunity].

  2023cites this paper
• Nanomaterials in Cancer Immunotherapy: A Spotlight on Breast Cancer

  2023cites this paper
• Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department

  2023cites this paper
• Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort

  2023cites this paper
• The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans

  2023cites this paper
• Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer

  2022cites this paper
• A Prognostic Signature for Clear Cell Renal Cell Carcinoma Based on Ferroptosis-Related lncRNAs and Immune Checkpoints

  2022cites this paper
• Neutrophil Infiltration and Acinar-ductal Metaplasia Are the Main Pathological Findings in Pembrolizumab-induced Pancreatitis

  2022cites this paper
• A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors

  2022cites this paper
• Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance

  2022cites this paper
• A review of the cutaneous toxicities of tebentafusp—Featuring two cases involving superficial bullous reactions

  2022cites this paper
• The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes

  2022cites this paper
• Novel markers in breast pathology

  2022cites this paper
• The Combined Use of Orf Virus and PAK4 Inhibitor Exerts Anti-tumor Effect in Breast Cancer

  2022cites this paper
• Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer

  2022cites this paper
• FDG PET/CT in Immune-Related Arthritis in a Patient Treated With Nivolumab.

  2022cites this paper
• CD8+ and FoxP3+ T‐Cell Cellular Density and Spatial Distribution After Programmed Death‐Ligand 1 Check Point Inhibition

  2022cites this paper
• The End of “One Size Fits All” Sepsis Therapies: Toward an Individualized Approach

  2022cites this paper
• The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship

  2022cites this paper
• Immune Checkpoint Inhibitors: Recent clinical advances and future prospects.

  2022cites this paper
• Effects of ginger extract and its major component 6-gingerol on anti-tumor property through mitochondrial biogenesis in CD8+ T cells.

  2022cites this paper
• Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment

  2021cites this paper
• Nephrotoxicity in immune checkpoint inhibitor therapy: a pharmacovigilance study.

  2021cites this paper
• Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy

  2021cites this paper
• Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature

  2021cites this paper
• A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy.

  2021cites this paper
• The impact of selenium on regulatory T cell frequency and immune checkpoint receptor expression in patients with diffuse large B cell lymphoma (DLBCL)

  2021cites this paper
• Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy

  2021cites this paper
• Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database

  2021cites this paper
• Comprehensive analysis of angiogenesis subtype of squamous cell carcinoma

  2021cites this paper
• Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma

  2021cites this paper
• The Treatment for a Patient with Cancer of Unknown Primary: A Case Report

  2021cites this paper
• Evaluation of dose distribution to organs-at-risk in a prospective phase 1 trial of pembrolizumab and multi-site stereotactic body radiotherapy (SBRT).

  2021cites this paper
• Malignant Melanoma: From Molecular Characterization to Targeted Therapies

  2021cites this paper
• Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor

  2021cites this paper
• Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures

  2021cites this paper
• Myasthenia gravis induced or exacerbated by immune checkpoint inhibitors: a rising concern

  2021cites this paper
• Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer

  2021cites this paper
• Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors

  2021cites this paper
• The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome

  2021cites this paper
• Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?

  2021cites this paper
• The role of CCR2 in prognosis of patients with endometrial cancer and tumor microenvironment remodeling

  2021cites this paper
• Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials

  2021cites this paper
• Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report.

  2021cites this paper
• Pembrolizumab Induced Acute Persistent Airway Disease in a Patient with Recurrent Respiratory Papillomatosis (RRP)

  2021cites this paper
• Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review

  2020cites this paper
• Efficacy and immune-related adverse event associations in avelumab-treated patients

  2020cites this paper
• Black phosphorus quantum dots doped multifunctional hydrogel particles for cancer immunotherapy

  2020cites this paper
• Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression

  2020cites this paper
• A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies

  2020cites this paper
• Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1

  2020cites this paper
• Immunotherapeutics to Treat HIV in the Central Nervous System

  2020cites this paper
• Translational considerations in nanomedicine: The oncology perspective.

  2020cites this paper
• Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database

  2020cites this paper
• Immune Checkpoint Inhibitor-induced Fanconi Syndrome

  2020cites this paper
• The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy

  2020cites this paper
• Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.

  2020cites this paper
• Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma

  2020cites this paper
• Differential expression of immune related genes in high-grade ovarian serous carcinoma.

  2020cites this paper
• Endometrial Cancer Immune Escape Mechanisms: Let Us Learn From the Fetal–Maternal Interface

  2020influential citation
• Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1

  2020cites this paper
• Peptide-Functionalized Delivery Vehicles for Enhanced Cancer Therapy.

  2020cites this paper
• Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells.

  2020cites this paper
• Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review

  2020cites this paper
• Tumor Lactic Acidosis: Protecting Tumor by Inhibiting Cytotoxic Activity Through Motility Arrest and Bioenergetic Silencing

  2020cites this paper
• Combination of Bacterial‐Photothermal Therapy with an Anti‐PD‐1 Peptide Depot for Enhanced Immunity against Advanced Cancer

  2019cites this paper
• Checkpoints and beyond - Immunotherapy in colorectal cancer.

  2019cites this paper
• Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?

  2019cites this paper
• Lactic Acid Bacteria as a Live Delivery System for the in situ Production of Nanobodies in the Human Gastrointestinal Tract

  2019cites this paper
• High‐dimensional single‐cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis

  2019cites this paper